ArticleFrontiers in pharmacology2019
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Genotoxicity assessment of Hwanglyeonhaedok-tang: an herbal formula evaluated using the in vivo alkaline comet assay and Pig-a gene mutation assay in rats.BMC complementary medicine and therapies · 2026Article
- β-hydroxybutyrate and ischemic stroke: roles and mechanisms.Molecular brain · 2024Review
- The Water Extract of Rhubarb Prevents Ischemic Stroke by Regulating Gut Bacteria and Metabolic Pathways.Metabolites · 2024Article
- Total cucurbitacins fromFrontiers in pharmacology · 2024Article
- Serum Metabolic Characterization of Vitamin E Deficiency inAnimals : an open access journal from MDPI · 2023Article
- Metabolomics: A useful tool for ischemic stroke research.Journal of pharmaceutical analysis · 2023Review
- Machine learning algorithms assisted identification of post-stroke depression associated biological features.Frontiers in neuroscience · 2023Article
- Repurposing the mucolytic agent ambroxol for treatment of sub-acute and chronic ischaemic stroke.Brain communications · 2023Article
- Peroxiredoxin 1 alleviates oxygen-glucose deprivation/ reoxygenation injury in N2a cells via suppressing the JNK/caspase-3 pathway.Iranian journal of basic medical sciences · 2023Article
- Exploration of the Protective Mechanism of Naringin in the Acetaminophen-Induced Hepatic Injury by Metabolomics.Oxidative medicine and cellular longevity · 2022Article
- Metabolomic Profiling of Brain Protective Effect of Edaravone on Cerebral Ischemia-Reperfusion Injury in Mice.Frontiers in pharmacology · 2022Article
- Application of Metabolomics to the Discovery of Biomarkers for Ischemic Stroke in the Murine Model: a Comparison with the Clinical Results.Molecular neurobiology · 2021Review
- Differentiation of gestational diabetes mellitus by nuclear magnetic resonance-based metabolic plasma analysis.Journal of biomedical research · 2021Article
- Recent Advances in Chinese Herbal Medicine for Cerebral Ischemic Reperfusion Injury.Frontiers in pharmacology · 2021Review
- Systems pharmacology reveals the mechanism of activity of Physalis alkekengi L. var. franchetii against lipopolysaccharide-induced acute lung injury.Journal of cellular and molecular medicine · 2020Article
- Intermodule Coupling Analysis of Huang-Lian-Jie-Du Decoction on Stroke.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huang-Lian-Jie-Du-Decoction (HLJDD) is a traditional Chinese medicine (TCM) used to treat ischemic stroke. However, the complexity of its chemical composition makes quality control difficult. Berberine, baicalin, and geniposide are the three main ingredients in HLJDD. Here, a formula of BBG comprised of berberine, baicalin, and geniposide, known as Refined-Huang-Lian-Jie-Du-Decoction, was investigated for its efficacy, therapeutic window, and mechanisms of action. BBG was assessed on two major types of ischemic stroke, cerebral ischemia-reperfusion (I/R) injury, and continuous ischemia injury, respectively. BBG showed efficacy comparable to HLJDD in the treatment of cerebral I/R injury within 5 h after injury initiation but did poorly in treating continuous ischemia injury. BBG exhibited neuroprotective effects on cerebral I/R injury by regaining the balance in energy metabolism, oxidative stress, amino acid metabolism, inflammation, and nucleic acid metabolism. These results suggested that BBG could be a good alternative to HLJDD, with high efficacy and a long therapeutic window, which shows great potential for drug development to treat stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.